DGX - Quest Diagnostics Incorporated

NYSE - NYSE Delayed Price. Currency in USD
103.38
+5.30 (+5.40%)
At close: 4:01PM EDT

103.38 0.00 (0.00%)
After hours: 4:17PM EDT

Stock chart is not supported by your current browser
Previous Close98.08
Open103.71
Bid103.36 x 800
Ask103.37 x 800
Day's Range101.57 - 104.90
52 Week Range78.95 - 112.38
Volume2,650,210
Avg. Volume990,757
Market Cap13.892B
Beta (3Y Monthly)0.89
PE Ratio (TTM)19.80
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.12 (2.16%)
Ex-Dividend Date2019-07-05
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Quest Diagnostics Reports Second Quarter 2019 Financial Results
    PR Newswire15 hours ago

    Quest Diagnostics Reports Second Quarter 2019 Financial Results

    - Second quarter revenues of $1.95 billion , up 1.8% from 2018 - Second quarter reported diluted earnings per share from continuing operations ("EPS") of $1.51 , down 3.9% from 2018; and adjusted ...

  • ACCESSWIRE15 hours ago

    Quest Diagnostics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 23, 2019 / Quest Diagnostics, Inc. (NYSE: DGX ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 8:30 AM Eastern ...

  • Business Wire4 days ago

    QUEST DIAGNOSTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Quest Diagnostics Incorporated - DGX

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Quest Diagnostics Incorporated .

  • Quest Diagnostics Welcomes New Members to the Global Diagnostics Network (GDN)
    PR Newswire6 days ago

    Quest Diagnostics Welcomes New Members to the Global Diagnostics Network (GDN)

    SECAUCUS, N.J., July 18, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, announced today the expansion of the Global Diagnostics Network (GDN), a strategic working group of major diagnostic laboratories collaborating to generate enhanced diagnostics insights to improve the delivery of global healthcare. Regional companies LSI Medience, and Strand Life Sciences join Quest and the charter members -- Al Borg Medical Laboratories, Dasa, GC Labs, Healius, KingMed Diagnostics, SYNLAB – as GDN members.

  • PR Newswire7 days ago

    Quest Diagnostics Named one of the "Best Places to Work for Disability Inclusion"

    SECAUCUS, N.J. , July 17, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has been named to the 2019 Disability Equality ...

  • Catholic Health Services Partners with Quest Diagnostics to Deliver High-Value, Innovative Laboratory Services
    PR Newswire7 days ago

    Catholic Health Services Partners with Quest Diagnostics to Deliver High-Value, Innovative Laboratory Services

    SECAUCUS, N.J. and ROCKVILLE CENTRE, N.Y., July 17, 2019 /PRNewswire/ -- Catholic Health Services (CHS), an integrated health care delivery system with a 24% market share on Long Island, is teaming up with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to enhance the quality and value of diagnostic services to patients and their doctors. "We are pleased to partner with Catholic Health Services, a leader in health care delivery on Long Island," said Quest Diagnostics Chairman, President and CEO Steve Rusckowski.

  • PR Newswire12 days ago

    Sharecare names Quest Diagnostics its preferred laboratory partner to advance digital health management

    ATLANTA, July 12, 2019 /PRNewswire/ -- Sharecare, the digital health company that helps people manage all their health in one place, and Quest Diagnostics (DGX) have formed a collaboration designed to improve digital health and disease management for a range of health care consumers. Sharecare has named Quest its preferred laboratory partner for its comprehensive digital health platform. Sharecare and Quest Diagnostics also intend to jointly explore the development of disease management programs and other services to empower better health.

  • Quest Diagnostics To Release Second Quarter 2019 Financial Results On July 23
    PR Newswire15 days ago

    Quest Diagnostics To Release Second Quarter 2019 Financial Results On July 23

    Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

  • QUEST DIAGNOSTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Quest Diagnostics Incorporated - DGX
    PR Newswirelast month

    QUEST DIAGNOSTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Quest Diagnostics Incorporated - DGX

    NEW ORLEANS , June 21, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...

  • Employer Wellness Screening with Digital Diabetes Prevention Program May Lower Eight-Year Risk of Diabetes, Suggests Quest Diagnostics Study
    PR Newswirelast month

    Employer Wellness Screening with Digital Diabetes Prevention Program May Lower Eight-Year Risk of Diabetes, Suggests Quest Diagnostics Study

    SECAUCUS, N.J., June 17, 2019 /PRNewswire/ -- Individuals with prediabetes who participate in an employer-sponsored digital diabetes-prevention counseling program may reduce their risk of developing type 2 diabetes (T2D) for up to eight years, according to a new study from Quest Diagnostics (DGX), the world's leading provider of diagnostic information services. The new study, "Digital Behavioral Counseling in a Workforce Setting Reduces 8-Year Risk of Developing Type 2 Diabetes" (77-LB), is believed to be the first to suggest lower risk of diabetes may be sustained following participation in a time-limited digital Diabetes Prevention Program (DPP).

  • GlobeNewswirelast month

    Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Quest Diagnostics Incorporated (NYSE: DGX) and Encourages Quest Diagnostics Investors to Contact the Firm

    NEW YORK, June 09, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Quest Diagnostics Incorporated (NYSE:.

  • PR Newswire2 months ago

    Faruqi & Faruqi, LLP is Investigating Quest Diagnostics Incorporated (DGX) on Behalf of its Shareholders

    NEW YORK , June 6, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Quest Diagnostics Incorporated ("Quest Diagnostics" ...

  • Quest Diagnostics Now Participating in NCI-MATCH Precision Medicine Clinical Trial
    PR Newswire2 months ago

    Quest Diagnostics Now Participating in NCI-MATCH Precision Medicine Clinical Trial

    SECAUCUS, N.J., May 29, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), a leading provider of diagnostic information services, today announced it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial, the largest precision medicine trial of its kind. The trial is co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). NCI-MATCH (EAY131) is a phase 2 precision medicine trial that seeks to determine the effectiveness of treatment that is directed by genomic profiling in patients with solid tumors, lymphomas, or myelomas that have progressed following standard treatments expected to prolong survival, or for rare cancer types for which there is no standard treatment.

  • Quest Diagnostics Declares Quarterly Cash Dividend
    PR Newswire2 months ago

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J. , May 14, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...

  • Quest Diagnostics To Speak At The UBS Global Healthcare Conference
    PR Newswire2 months ago

    Quest Diagnostics To Speak At The UBS Global Healthcare Conference

    SECAUCUS, N.J., May 13, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the UBS Global Healthcare Conference in New York.  Steve Rusckowski, Chairman, President and CEO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

  • ACCESSWIRE3 months ago

    Key Healthcare Stocks To Watch as US Markets Approach Record Highs

    CORAL GABLES, FL / ACCESSWIRE / April 24, 2019 / If there was one industry to be aware of right now, it's the healthcare industry. Definitive Healthcare's 2019 Annual Healthcare Trends Survey cited these two factors as major drivers to the future growth of the market. Today we are highlighting: Teladoc Health, Inc. (TDOC), TELUS Corporation (TU) (TSX:T.TO), Quest Diagnostics Incorporated (DGX), Premier Health Group (PHGRF) (PHGI.CN).

  • Quest Diagnostics Reports First Quarter 2019 Financial Results
    PR Newswire3 months ago

    Quest Diagnostics Reports First Quarter 2019 Financial Results

    - First quarter revenues of $1.89 billion , up 0.4% from 2018 - First quarter reported diluted EPS of $1.20 , down 5.4% from 2018; and adjusted diluted EPS of $1.40 , down 7.9% from 2018 - Cash provided ...

  • Forbes Names Quest Diagnostics One of America's Best Large Employers
    PR Newswire3 months ago

    Forbes Names Quest Diagnostics One of America's Best Large Employers

    Quest was among one of only fifteen companies in the Health Care Equipment and Services category to attain the designation. Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

  • Quest Diagnostics Launches New Consumer-Initiated STD Tests Through QuestDirect™
    PR Newswire3 months ago

    Quest Diagnostics Launches New Consumer-Initiated STD Tests Through QuestDirect™

    SECAUCUS, N.J., April 18, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States. The new STD test packages are the first to be offered directly by Quest Diagnostics or any other major national laboratory to allow individuals to purchase tests at their discretion.

  • Workforce Drug Testing Positivity Climbs to Highest Rate Since 2004, According to New Quest Diagnostics Analysis
    PR Newswire3 months ago

    Workforce Drug Testing Positivity Climbs to Highest Rate Since 2004, According to New Quest Diagnostics Analysis

    Analysis of more than ten million workplace drug test results shows increases in marijuana positivity across nearly all employee testing categories Increases in post-accident positivity in the general ...

  • Quest Diagnostics To Release First Quarter 2019 Financial Results On April 23
    PR Newswire4 months ago

    Quest Diagnostics To Release First Quarter 2019 Financial Results On April 23

    A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-480-3547 for domestic callers or 203-369-1551 for international callers, no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on April 23, 2019 until midnight Eastern Time on May 7, 2019. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

  • Quest Diagnostics Presents Supplier Excellence Awards to Four Partners
    PR Newswire4 months ago

    Quest Diagnostics Presents Supplier Excellence Awards to Four Partners

    SECAUCUS, N.J. , April 3, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today awarded Supplier Excellence awards to four companies ...

  • Quest Diagnostics Achieves Perfect Score On 2019 Human Rights Campaign Corporate Equality Index for Third Consecutive Year
    PR Newswire4 months ago

    Quest Diagnostics Achieves Perfect Score On 2019 Human Rights Campaign Corporate Equality Index for Third Consecutive Year

    SECAUCUS, N.J. , April 1, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, received a perfect score of 100 from the Human ...

  • Massachusetts Governor Baker Visits State of the Art Quest Diagnostics Marlborough Laboratory
    PR Newswire4 months ago

    Massachusetts Governor Baker Visits State of the Art Quest Diagnostics Marlborough Laboratory

    During the visit Governor Baker toured the laboratory, met with employees, and learned more about the company's initiatives in the areas of pricing transparency, Alzheimer's treatment and detection, and combatting the opioid epidemic. "Thanks to companies like Quest Diagnostics, Massachusetts continues to be a global leader in the innovation and life sciences industry," said Governor Charlie Baker.